AGMB (AgomAb Therapeutics NV) Other Operating Expense: $-0.69 Mil (TTM As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Other Operating Expense?

AgomAb Therapeutics NV AGMB +0.85% 14 Other Operating Expense is $-0.69 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AgomAb Therapeutics NV's Other Operating Expense for the three months ended in Dec. 2025 was $-0.69 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.69 Mil.

AgomAb Therapeutics NV's quarterly Other Operating Expense increased from Dec. 2024 ($-0.31 Mil) to Sep. 2025 ($0.00 Mil) but then declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.69 Mil).

AgomAb Therapeutics NV's annual Other Operating Expense increased from Dec. 2023 ($-1.22 Mil) to Dec. 2024 ($-1.16 Mil) but then declined from Dec. 2024 ($-1.16 Mil) to Dec. 2025 ($-2.54 Mil).

AgomAb Therapeutics NV Other Operating Expense Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Other Operating Expense Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
0.00 -1.35 -1.22 -1.16 -2.54

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Other Operating Expense Get a 7-Day Free Trial 0.00 0.00 -0.31 0.00 -0.69
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.69 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Other Operating Expense of $-0.69 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Other Operating Expense too high?
AgomAb Therapeutics NV's current Other Operating Expense is $-0.69 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Other Operating Expense compare to DNA and ACRS?
AgomAb Therapeutics NV's Other Operating Expense of $-0.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Other Operating Expense is $-0.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Other Operating Expense of $-0.69 Mil. The current Other Operating Expense is $-0.69 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Other Operating Expense is $-0.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price